Calvin Yu
Keine laufenden Positionen mehr
Ursprung des Netzwerks ersten Grades von Calvin Yu
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 12 | |
| Subsidiary | Biotechnology | 11 | |
Stemcentrx, Inc.
 Stemcentrx, Inc. BiotechnologyHealth Technology Stemcentrx, Inc. develops life-changing therapies for cancer patients. It develops proprietary discovery platforms that yield unprecedented insight into the biology of tumors and are being exploited to develop potent new cancer drugs. The firm specializes in designing drugs to target cancer stem cells, which are the cells that cause cancer to spread throughout the body. The company was founded by Brian Christopher Slingerland, Daniel T. Reiner and Scott J. Dylla in 2008 and is headquartered in San Francisco, CA.
1
| Extinct | Biotechnology | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Calvin Yu
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| University of California, Berkeley | College/University | Graduate Degree Graduate Degree Undergraduate Degree Undergraduate Degree | |
Verana Health, Inc.
 Verana Health, Inc. Packaged SoftwareTechnology Services Verana Health, Inc. engages in the development of software solutions for remote patient monitoring and data analytics. It focuses on bridging the gap between healthcare providers and patients with mobile tests. The company was founded by Mark S. Blumenkranz and Daniel V. Palanker in 2008 and is headquartered in San Francisco, CA. | Packaged Software | Director/Board Member Founder Director/Board Member | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Stanford University | College/University | Director/Board Member Corporate Officer/Principal Doctorate Degree | |
| Georgia Institute of Technology | College/University | Undergraduate Degree Undergraduate Degree | |
| CYTOKINETICS, INCORPORATED | Pharmaceuticals: Major | Private Equity Investor Director/Board Member | |
| Stanford University School of Medicine | College/University | Corporate Officer/Principal Doctorate Degree | |
Oculeve, Inc.
 Oculeve, Inc. Medical SpecialtiesHealth Technology Oculeve, Inc. develops devices for dry eye disease treatment. The company was founded by D. Michael Ackermann, Brandon M. Felkins, Garrett Cale Smith and Victor Wayne McCray in 2011 and is headquartered in Parsippany, NJ. | Medical Specialties | Director/Board Member Founder | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| The University of California, San Francisco | College/University | Corporate Officer/Principal Doctorate Degree | |
Kuur Therapeutics Ltd.
 Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
Strateos, Inc.
 Strateos, Inc. Medical SpecialtiesHealth Technology Strateos engages in the automation of chemistry, biology, and tissue analysis into closed loop robotic laboratories that support drug discovery programs. The company is headquartered in the Menlo Park, CA. | Medical Specialties | Director/Board Member | |
Transcriptic, Inc.
 Transcriptic, Inc. Medical SpecialtiesHealth Technology Transcriptic, Inc. engages in the conversion of biology into an information technology, driven by data, and computation. It specializes in biology, automation, and software engineering. The company was founded by Max Joseph Hodak on February 14, 2012 and is headquartered in Menlo Park, CA. | Medical Specialties | Director/Board Member | |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Miscellaneous Commercial Services | Director/Board Member | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree | |
Septerna, Inc.
 Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Pharmaceuticals: Major | Founder | |
| INNOVIVA, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| California School of Professional Psychology | College/University | Doctorate Degree | |
| Bar-Ilan University | College/University | Graduate Degree | |
Ambys Medicines, Inc.
 Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Ambys Medicines, Inc. develops regenerative medicine therapies for serious liver diseases. The company was founded by Martin Burke, Markus Grompe, Juan Carlos Izpisua Belmonte and Holger Willenbring and is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member | |
| THERAVANCE BIOPHARMA, INC. | Pharmaceuticals: Major | Private Equity Investor | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Undergraduate Degree | |
| CLOVIS ONCOLOGY, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| IGM BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
| IDEAYA BIOSCIENCES, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Arch Oncology, Inc.
 Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Miscellaneous Commercial Services | Chief Executive Officer | |
| Case Western Reserve University School of Medicine | College/University | Doctorate Degree | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
| SPRINGWORKS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Accent Therapeutics, Inc.
 Accent Therapeutics, Inc. BiotechnologyHealth Technology Accent Therapeutics, Inc. operates as a biopharmaceutical company which develops treatments for cancer patients. The company was founded by Howard Y. Chang, Chuan He and Robert A. Copeland in September 2017 and is headquartered in Lexington, MA. | Biotechnology | Director/Board Member | |
| ERASCA, INC. | Pharmaceuticals: Major | Director/Board Member | |
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Pharmaceuticals: Major | Director/Board Member | |
SparingVision SAS
 SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Biotechnology | Chief Operating Officer | |
Genethon
 Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Biotechnology | Corporate Officer/Principal | |
| Clinvec Solutions LLC | Miscellaneous | Corporate Officer/Principal | |
| Byers Eye Institute | Corporate Officer/Principal | ||
| Oculogics, Inc. | Director/Board Member | ||
| Association of University Professors of Ophthalmology | President | ||
| Macula Society | President | ||
| The Retina Society | President | ||
Vantage Surgical Systems, Inc.
 Vantage Surgical Systems, Inc. Medical SpecialtiesHealth Technology Vantage Surgical Systems, Inc. develops medical imaging systems for minimally invasive procedures. The private company is based in Los Angeles, CA. The CEO of the company is Zohar Loshitzer. | Medical Specialties | Director/Board Member | |
Presbia USA, Inc.
 Presbia USA, Inc. Medical SpecialtiesHealth Technology Part of Presbia PLC, Presbia USA, Inc. is a medical device manufacturer. The CEO of the American company is Zohar Loshitzer. | Medical Specialties | Director/Board Member | |
| PRESBIA PLC | Medical Specialties | Director/Board Member | |
Lagunita Biosciences LLC
 Lagunita Biosciences LLC Investment ManagersFinance Lagunita Biosciences LLC (Lagunita Biosciences) is a venture Capital firm founded in 2015 by Mark S. Blumenkranz. The firm is headquartered in Menlo Park, California. | Investment Managers | Founder | |
Presbia Holdings LLC
 Presbia Holdings LLC Miscellaneous Commercial ServicesCommercial Services Presbia Holdings LLC operates as a medical device firm. The company is headquartered in Los Angeles, CA. | Miscellaneous Commercial Services | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 45 |
| Frankreich | 3 |
| Vereinigtes Königreich | 2 |
| Israel | 2 |
| Irland | 2 |
Sektoral
| Health Technology | 27 |
| Consumer Services | 11 |
| Commercial Services | 5 |
| Finance | 4 |
| Technology Services | 2 |
Operativ
| Director/Board Member | 144 |
| Corporate Officer/Principal | 64 |
| Independent Dir/Board Member | 43 |
| Undergraduate Degree | 21 |
| Chairman | 20 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Brook Byers | 53 |
| Franklin Berger | 41 |
| Mark Blumenkranz | 36 |
| Julia Gregory | 22 |
| Paul Cleveland | 18 |
| Linda Bain | 15 |
| Julie Hambleton | 15 |
| Jeffrey Finer | 12 |
| Thomas Chalberg | 11 |
| Min MIn Qin | 11 |
| Peder Jensen | 10 |
| Luis Borges | 9 |
| Francis Sarena | 9 |
| Galya Blachman | 9 |
| Mehdi Gasmi | 8 |
